IRWD Earnings Date: Nov 5, 2026 (Estimated) — Ironwood Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is IRWD's next earnings date?
Ironwood Pharmaceuticals, Inc. (IRWD) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.32 on revenue of $120.0M.
How did IRWD do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Ironwood Pharmaceuticals, Inc. posted EPS of $0.31 versus the $0.32 estimate, a miss of 14.8%. Revenue was $113.0M against a $114.8M estimate. The stock's 1-day post-earnings move was +2.7%.
How much does IRWD stock move after earnings?
IRWD beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.5% (up or down) in the day after earnings.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.32 | 0.31 | +14.81% | $113.0M | ❌ Miss | +2.65% | +4.10% | +3.37% |
| 2026-05-07 | Q1 2026 | 0.21 | 0.24 | +14.29% | $106.5M | ✅ Beat | -13.66% | -23.81% | -31.47% |
| 2026-02-25 | Q4 2025 | 0.01 | -0.01 | -200.00% | $47.7M | ❌ Miss | -11.35% | -3.96% | -15.83% |
| 2025-11-10 | Q3 2025 | 0.11 | 0.24 | +118.18% | $122.1M | ✅ Beat | +31.77% | +63.54% | +88.02% |
| 2025-02-27 | Q4 2024 | 0.08 | 0.02 | -75.00% | $90.5M | ❌ Miss | -5.26% | -9.94% | -14.62% |
| 2024-11-07 | Q3 2024 | 0.08 | 0.02 | -75.00% | $91.6M | ❌ Miss | -7.54% | -14.58% | -31.94% |
| 2024-05-09 | Q1 2024 | 0.20 | -0.02 | -110.00% | $74.9M | ❌ Miss | -17.00% | -19.21% | -21.80% |
| 2024-02-15 | Q4 2023 | 0.21 | 0.00 | -100.00% | $117.6M | ❌ Miss | -2.98% | -3.82% | -41.62% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $1.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Royalty | 73.5% | $1.1M | +22.2% | — | $800K | $900K | $900K |
| Collaborative Arrangement, Collaboration and License Agreements | 26.5% | $397K | — | — | — | — | — |
By region
Q2 FY26 · $112.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 99.0% | $110.9M | +28.3% | $181.3M | $39.4M | $86.4M | $120.5M |
| Europe and Other | 1.0% | $1.1M | +23.1% | $1.7M | $811K | $904K | $944K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.